The Scripps Research Institute

The United States of America As Represented by the Secretary of

Emergent Product Development Gaithersburg Inc.

Angray Singh Kang

Richard A Lerner

Carlos F Barbas

Carlos F Barbas, Iii

Wolfgang Scholz

Ritsuko Sawada

Fei Wang

Barry Baxt

Peter W Mason

Analia Berinstein

Elizabeth Reider

Jeanne Morrow, Legal Representative

Ivy Jiang

Filamentous phage comprising a matrix of cpVIII proteins encapsulating a genome encoding first and second polypeptides of an antogenously assembling receptor, such as an antibody, and a receptor comprised of the first and second polypeptides surface-integrated into the matrix via a filamentous phage coat protein membrane anchor domain fused to at least one of the polypeptides.

Heterodimeric receptor libraries using phagemids

A highly efficient method for generating human antibodies using recall technology is provided. In one aspect, human antibodies which are specific to the anthrax toxin are provided. In one aspect, human peripheral blood cells that have been pre-exposed to anthrax toxin are used in the SCID mouse model. This method results in high human antibody titers which are primarily of the IgG isotype and which contain antibodies of high specificity and affinity to desired antigens. The antibodies generated by this method can be used therapeutically and prophylactically for preventing or treating mammals exposed to anthrax. Thus, in one embodiment, a prophylactic or therapeutic agent used to counter the effects of anthrax toxin, released as a mechanism of bioterrorism, is provided. In one embodiment, a formulation and method for preventing and/or treating anthrax infection comprising a binding agent that prevents the assembly of the PA63 heptamer is also provided. Methods for diagnosis and methods to determine anthrax contamination are also described.

Antibodies against protective antigen and methods of use for passive immunization and treatment of anthrax

Immunization and treatment methods for anthrax

A modified filamentous phage that contains a gene for a wild type phage coat protein and a gene for a synthetic phage coat protein is provided. Uses of the modified phage and kits containing the phage are also provided.

Modulation of polypeptide display on modified filamentous phage use

The present invention relates to multispecific and multivalent antigen-binding polypeptides and methods for producing them.

Multispecific and multivalent antigen-binding polypeptide molecules

Filamentous phage comprising a matrix of cpvIII proteins encapsulating a genome encoding first and second polypeptides of an antogenously assembling receptor, such as an antibody, and a receptor comprised of the first and second polypeptides surface-integrated into the matrix via a filamentous phage coat protein membrane anchor domain fused to at least one of the polypeptides.

Modulation of polypeptide display on modified filamentous phage

Filamentous phase comprising a matrix of cpVIII proteins encapsulating a genome encoding first and second polypeptides of an antogenously assembling receptor, such as an antibody, and a receptor comprised of the first and second polypeptides surface-integrated into the matrix via a filamentous phage coat protein membrane anchor domain fused to at least one of the polypeptides.

Hetrodimeric receptor libraries using phagemids

Filamentous phage comprising a matrix of cpVIII proteins encapsulating a genome encoding first and second polypeptides of an autogenously assembling receptor, such as an antibody, and a receptor comprised of the first and second polypeptides surface-integrated into the matrix via a cpVIII membrane anchor domain fused to at least on of the polypeptides.

A method of making a genetically-engineered cell line which is susceptible to infection by foot-and-mouth disease virus and allows the virus to replicate is disclosed. The method involves fusing the DNA encoding ICAM-1 with the DNA encoding an antibody specific for foot-and-mouth disease virus and expressing the resulting chimeric cell surface receptor protein. The chimeric cell surface receptor protein allows foot-and-mouth disease virus to bind, leading to subsequent infection and replication of foot-and-mouth disease virus. A genetically-engineered cell which expresses the chimeric cell surface receptor protein is also claimed.

Cell line for propagating receptor binding site-deleted FMDV

A safe, effective vaccine for the protection of susceptible animals against foot-and-mouth disease has been produced. The vaccine comprises a mutant virus from which the amino acid sequence Gly-Val-Arg-Gly-Asp-Phe (SEQ ID NO: 8) from the G-H loop of VP1 has been deleted and replaced with the amino acid sequence Asn-Pro. The mutant virus retains its antigenicity but is not infectious.

Growing community of inventors

Carlsbad, CA, United States of America

Angray Singh Kang